Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc (NQ: DNLI )

15.60 -0.51 (-3.20%)
Streaming Delayed Price Updated: 3:48 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 486,471
Open 16.10
Bid (Size) 15.59 (6)
Ask (Size) 15.60 (4)
Prev. Close 16.11
Today's Range 15.47 - 16.30
52wk Range 15.45 - 33.31
Shares Outstanding 121,640,069
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
To the Moon and Beyond: 7 Stocks With Cosmic Potential
With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential. 
Via InvestorPlace
Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know
Via Benzinga

Performance

YTD
-27.09%
-27.09%
1 Month
-21.51%
-21.51%
3 Month
-8.80%
-8.80%
6 Month
-20.84%
-20.84%
1 Year
-37.49%
-37.49%

More News

Read More
4 Analysts Assess Denali Therapeutics: What You Need To Know
Via Benzinga
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Denali Therapeutics: Q4 Earnings Insights
Via Benzinga
The Latest Analyst Ratings for Denali Therapeutics
Via Benzinga
Where Denali Therapeutics Stands With Analysts
Via Benzinga
Analyst Expectations for Denali Therapeutics's Future
Via Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Where Denali Therapeutics Stands With Analysts
Via Benzinga
Denali Therapeutics Announces $500 million Private Placement Equity Financing
From Denali Therapeutics Inc.
Via GlobeNewswire
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
Via Benzinga
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
Via InvestorPlace
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
From Denali Therapeutics Inc.
Via GlobeNewswire
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
Via InvestorPlace
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.